Using Biomarkers to Inform COVID-19 Treatment

Help Determine and Prevent Risk for Long-Term Side Effects

Infection with SARS-CoV-2 results in COVID-19. This infection has systemic manifestations, including acute lung injury, cardiac damage, and in rare cases a Kawasaki disease-like illness. With rising cases of COVID-19 nationally, clinicians can benefit from tools to inform decisions regarding triage, advanced imaging, and treatment.

Biomarker testing has emerged as a potentially useful tool to facilitate clinical decision making. It can highlight risks in patients with COVID-19, prognosticating poor outcome, and help determine where patients should be admitted (e.g., medical floor vs. ICU), how they should be imaged, and whether to apply more advanced treatments.

In this P.A.C.E.-accredited Fisher Healthcare webinar presented by Dr. James Louis Januzzi, review of data will focus on use of troponins, natriuretic peptides, and other biomarkers in a clinically focused synthesis of how biomarkers might be used in COVID-19 assessment.

Learning Objectives

This webinar will help you:

• Recite causes of cardiac injury in COVID-19 patients
• Relate the development of a Kawasaki disease-like illness to COVID-19
• List biomarkers with potential utility in COVID-19 treatment
• Develop a strategy to use biomarkers to enhance clinical care for COVID-19 patients

Watch on Demand       Download Slides (PDF, 2.1MB)

For research use only. Not for diagnostic procedures.

This webinar is produced by Whitehat Communications, a provider of continuing education programs in clinical laboratory sciences that has been approved by the ASCLS P.A.C.E.™ Program. One P.A.C.E. credit hour will be provided for this complimentary, basic-level program.

James Louis Januzzi, MD

Dr. James Januzzi is a member of the Cardiology Division of the Massachusetts General Hospital and the Hutter Family Professor of Medicine at Harvard Medical School. He is an accomplished clinician and clinical trialist, with a research focus on biomarker testing in cardiovascular disease. Januzzi has authored more than 650 publications and is an editor of two American College of Cardiology journals.